Contineum’s PROPEL-IPF Progress and Upcoming Catalysts Support Buy Rating; $30 Price Target Unchanged
at www.tipranks.com (Tue, 3-Nov 7:15 PM)
Contineum Therapeutics GAAP EPS of -$0.49
at seekingalpha.com (Tue, 3-Nov 5:31 PM)
